ABI
VTRS icon

Adamant Biomedical Investments’s Viatris VTRS Stock Holding History

Adamant Biomedical Investments’s Portfolio VTRS Stock Details VTRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$11.3M Sell
200,000
-30,000
-13% -$1.61M 2.69% 7
2014
Q3 		$10.5M Buy
+230,000
New +$11.2M 2.61% 8

Other funds holding VTRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adamant Biomedical Investments's VTRS Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its Viatris (VTRS) stake by 13% in Q4 2014, selling an estimated $1.61M and leaving 200,000 shares worth $11.3M. The position accounts for 2.69% of the portfolio, ranked #7.

Adamant Biomedical Investments first reported a position in VTRS in Q3 2014 and has held it in 2 quarters since. 661 funds tracked by Wall St. Rank hold VTRS as of Q4 2014.

  • Adamant Biomedical Investments held 200,000 shares of Viatris worth $11.3M as of Q4 2014.
  • Adamant Biomedical Investments sold 30,000 Viatris shares in Q4 2014, an estimated $1.61M.
  • Viatris made up 2.69% of Adamant Biomedical Investments's portfolio in Q4 2014, its #7 holding.
  • Adamant Biomedical Investments first reported a position in Viatris in Q3 2014 and has held it in 2 quarters since.
  • 661 funds tracked by Wall St. Rank held Viatris as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.